Scientific Online Resource System

Scripta Scientifica Medica

Anti-Müllerian hormone - A hormone with narrow spectrum of action and broad spectrum of clinical significance

Vilhelm Mladenov


AMH (Anti-Müllerian Hormone, Müllerian Inhibiting Substance or Factor) is a member of the transforming growth factor - " family, secreted by the fetal and prepubertal testicular Sertoli cells, and to a lesser amount by the granulosa cells of the small ovarian follicles. It plays an important role in the shaping of the male reproductive tract and is one of the baseline hormones in the diagnostics of the disorders of the sex development in the male. In the female, in the recent years AMH has become an important clinical tool for evaluation of the ovarian follicular reserve, for predicting ovarian response to gonadotropin stimulation in IVF treatment and for the diagnosis of hyperandrogenism. Recombinant AMH is a promising medication for the treatment of gynecological cancers and endometriosis.

Full Text


Josso N, Rey RA, Picard JY. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol. 2013;2013:674105.

Grinspon RP, Rey RA. Anti-müllerian hormone and sertoli cell function in paediatric malehypogonadism. Horm Res Paediatr. 2010;73(2):81-92.

Lashen H, Dunger DB, Ness A, Onq KK. Peripubertal changes in circulating antimüllerian hormone levels in girls. Fertil Steril. 2013 Jun;99(7):2071-5.

Leader B, Baker VL. Maximizing the clinical utility of antimüllerian hormone testing in women`s health. Curr Opin Obstet Gynecol 2014, 26(4):226-36.

Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, et al. Serum antimüllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012; 97(12): 4650-5.

Lindhardt Johansen M, Hagen CP, Johansen TH, Main KM, Picard JY, Jorgensen A, et al. Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013;2013:198698.

Hughes IA, Houk C, Ahmed SF; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006;91(7):554-63

Ahmed SF, Rodie M. Investigation and initial management of ambiguous genitalia. Best Pract Res Clin Endocrinol Metab. 2010;24(2):197-218 9. Grinspon RP, Andreone L, Bedecarras P, Ropelato MG, Rey RA, Campo SM, et al. Male central precocious puberty: serum profile of anti-müllerian hormone and inhibin B before, during, and after treatment with GnRH Analogue. Int J Endocrinol. 2013;2013:823064

Kim JH, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-müllerian hormone: a novel treatment for gynecologic tumors. Obstet Gynecol Sci 2014;57(5):343-57

Signorile PG, Petraglija F, Baldi A. Anti-mullerian hormone is expressed by endometriosis tissues and induces cell cycle arrest and apoptosis in endometriosis cells. J Exp Clin Cancer Res. 2014 May 29;33:46.

Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014 Mar 26;12:26

Krawzcuk-Rybak M, Leszczynska E, Poznanska M, Zelazowska-Rutkowska B, Wysocka J. Antimüllerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol. 2013;2013:125080

Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the childhood cancer survivor study. J Clin Oncol. 2009 May 10;27(14):2374-81

Brougham M F, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-müllerian hormone is a marker of gonadotoxicity in preand postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012 Jun;97(6):2059-67

Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014 Oct;31(10):1311-6

Bungum L, Franssohn F, Bungum M, Humaidan P, Giwercman A. The circadian variation in antimüllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. PLoS One. 2013 Sep 4;8(9):e68223

Lin YH, Chiu WC, Wu CH, Tzeng CR, Sen Hsu C, Hsu MI. Antimullerian hormone and polycystic ovary syndrome. Fertil Steril. 2011;96(1):230-5.

Pawelczak M, Kenigsberg L, Milla S, Liu YH, Shah B. Elevated serum anti-müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab. 2012; 25(9-10): 983-9.

Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Nq EH. Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-müllerian hormone and antral follicle count measurements: a retrospective study. PLoS One. 2014 Oct 14;9(10):e108493

Giudice LC, Kao LC. Endometriosis. Lancet 2004 Nov 13-19;364(9447):1789-99.

Article Tools
Email this article (Login required)
About The Author

Vilhelm Mladenov
UMHAT `Sveta Marina`, First Pediatric Clinic

Font Size